Urinary bladder cancer is the fifth most common cancer in the Western world. Increasing
evidence has shown that DNA methylation in bladder cancer is expansive and is implicated …

Background Although non muscle invasive bladder cancer (NMIBC) generally has a good
long-term prognosis, up to 80% of patients will nevertheless experience local recurrence …

DNA hypermethylation has emerged as a molecular biomarker for the evaluation of cancer
diagnosis and prognosis. We define a methylation signature of bladder cancer and evaluate …

Approximately 500,000 individuals diagnosed with bladder cancer in the US require routine
cystoscopic follow-up to monitor for disease recurrences or progression, resulting in over $2 …

There is increasing evidence for the role of epigenetic gene silencing in superficial bladder
cancer. The aim of the current study was to investigate the prognostic value of epigenetic …

A compelling body of evidences sustains the importance of epigenetic mechanisms in the
development and progression of cancer. Assessing the epigenetic component of bladder …

Background Bladder cancer is the sixth most common cancer in the world and the incidence
is particularly high in southwestern Taiwan. Previous studies have identified several tumor …

Background Current standard methods used to detect and monitor bladder cancer (BC) are
invasive or have low sensitivity. This study aimed to develop a urine methylation biomarker …

Urothelial cell carcinomas (UCC), including bladder cancer and upper urinary tract cancer,
are the second most common malignancy of the urogenital tract after prostate cancer. It is a …

We investigated the aberrant promoter methylation profile of bladder cancers and correlated
the data with clinicopathological findings. The methylation status of 10 genes was …